36.00
Schlusskurs vom Vortag:
$31.00
Offen:
$31.01
24-Stunden-Volumen:
644.93K
Relative Volume:
5.89
Marktkapitalisierung:
$398.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+29.96%
1M Leistung:
+63.27%
6M Leistung:
+173.76%
1J Leistung:
+0.00%
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Firmenname
Palvella Therapeutics Inc
Sektor
Branche
Telefon
(484) 253-1461
Adresse
125 STRAFFORD AVE, WAYNE
Vergleichen Sie PVLA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PVLA
Palvella Therapeutics Inc
|
36.00 | 306.24M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-21 | Eingeleitet | Truist | Buy |
2025-04-09 | Eingeleitet | Chardan Capital Markets | Buy |
2025-03-26 | Eingeleitet | Stifel | Buy |
2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
2025-02-20 | Eingeleitet | Canaccord Genuity | Buy |
2025-02-05 | Eingeleitet | TD Cowen | Buy |
2024-12-26 | Eingeleitet | H.C. Wainwright | Buy |
2024-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
2020-03-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2019-07-30 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2019-05-14 | Eingeleitet | Robert W. Baird | Outperform |
2018-03-19 | Eingeleitet | Evercore ISI | Outperform |
2018-03-19 | Eingeleitet | Jefferies | Buy |
2018-01-16 | Bestätigt | H.C. Wainwright | Buy |
2017-05-30 | Eingeleitet | Rodman & Renshaw | Buy |
2016-08-05 | Fortgesetzt | ROTH Capital | Buy |
2015-08-12 | Eingeleitet | JMP Securities | Mkt Outperform |
2015-07-27 | Eingeleitet | Oppenheimer | Outperform |
2015-07-22 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten
Palvella Therapeutics Inc. Stock Analysis and ForecastExceptional profit velocity - jammulinksnews.com
What analysts say about Palvella Therapeutics Inc. stockHigh-yield portfolio picks - jammulinksnews.com
Truist Securities initiates Palvella Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
What drives Palvella Therapeutics Inc. stock priceSuperior stock growth - jammulinksnews.com
Is Palvella Therapeutics Inc. a good long term investmentRapidly growing investment returns - Autocar Professional
What makes Palvella Therapeutics Inc. stock price move sharplyLow Risk Consistent Winners - Newser
Why Palvella Therapeutics Inc. stock attracts strong analyst attentionLow Risk Entry Points - Newser
How Palvella Therapeutics Inc. stock performs during market volatilityTop Performing Low Risk Stocks - Newser
Palvella Therapeutics Secures New Patent for QTORIN™ Rapamycin - MSN
Palvella Therapeutics Completes Enrollment for Pivotal Phase 3 Trial of QTORIN Rapamycin - Insider Monkey
Is Palvella Therapeutics (NASDAQ:PVLA) A Risky Investment? - simplywall.st
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of “Buy” by Analysts - Defense World
2,516 Shares in Palvella Therapeutics, Inc. (NASDAQ:PVLA) Purchased by Spire Wealth Management - Defense World
Palvella Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN
Palvella Therapeutics, Inc.(NasdaqCM: PVLA) added to Russell 3000 Value Index - MarketScreener
Palvella Therapeutics, Inc. Added to Russell 3000® and Russell 2000® Indexes as of June 30, 2025 - Nasdaq
Breakthrough Therapy: Phase 3 Trial Exceeds Target by 25% for First-Ever Microcystic LM Treatment - Stock Titan
Palvella Therapeutics Receives US Patent for Qtorin Topical Gel Candidate - MarketScreener
Palvella Therapeutics Granted Sixth U.S. Patent Covering - GlobeNewswire
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1-20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors - The Manila Times
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of - Bluefield Daily Telegraph
Palvella's Game-Changing QTORIN Patent Locks in 15+ Years of Market Protection for Rare Disease Treatment - Stock Titan
Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin - MSN
Cantor Fitzgerald Weighs in on PVLA FY2026 Earnings - Defense World
Palvella Therapeutics Holds Annual Stockholders Meeting - TipRanks
Palvella Therapeutics (NASDAQ:PVLA) Receives $46.29 Consensus Price Target from Analysts - Defense World
Palvella Therapeutics receives FDA grant for rare disease trial By Investing.com - Investing.com South Africa
Palvella Therapeutics Says Top-Line Data From SELVA Expected In Q1 2026 - marketscreener.com
Palvella Therapeutics receives FDA grant for rare disease trial - Investing.com
Palvella Therapeutics Receives Initial Proceeds from FDA - GlobeNewswire
Citadel Advisors LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA) - Defense World
Palvella Therapeutics Names Ashley Kline Chief Commercial Officer - MSN
Palvella Therapeutics Advances in Rare Skin Disease Therapies - TipRanks
A great week for institutional investors who own 26% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) - simplywall.st
Palvella Therapeutics Strengthens Executive Leadership Team - GlobeNewswire
Palvella Therapeutics hires Ashley Kline as Chief Commercial Officer - Investing.com
Palvella Therapeutics hires Ashley Kline as Chief Commercial Officer By Investing.com - Investing.com India
Finanzdaten der Palvella Therapeutics Inc-Aktie (PVLA)
Es liegen keine Finanzdaten für Palvella Therapeutics Inc (PVLA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):